Fighting cancer with next generation oncolytic immunotherapy in ovarian, head & neck, and lung cancers (Immune Checkpoint Response Enabling Adenovirus Technology )

Informazioni relative al progetto

I-CREATE

ID dell’accordo di sovvenzione: 190121193

DOI 10.3030/190121193

Progetto chiuso

Data della firma CE 11 Novembre 2022

Data di avvio 1 Luglio 2022

Data di completamento 31 Dicembre 2023

Finanziato da

• The European Innovation Council (EIC)

Costo totale € 5 073 000,00

Contributo UE € 2 100 000,00

Coordinato da

TILT BIOTHERAPEUTICS OY
Finland

Risultati finali

Documents, reports (1)

Interim clinical data from at least 3 patients

Deliverable relates to reporting of interim results of the ongoing clinical studies T115 T215

Websites, patent fillings, videos etc. (2)

First-patients treated

Update on the trial progress in the first study sites in Docrates finland and Mayo Clinic Minnesota

IND/clinical trial approved (T776)

IND approved for T776 headneck cancer clinical trial